C225 WITH CHEMORADIATION FOR POST-OP HEAD AND NECK SQUAMOUS CELL CANCER

C225 联合放化疗治疗术后头颈鳞状细胞癌

• 批准号: 7603210
• 负责人: RUBY F. MEREDITH
• 金额: $ 0.55万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603210
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Funding; Grant; Head and neck structure; Institution; Malignant Squamous Cell Neoplasm; Monoclonal Antibody C225; Patients; Phase; Phase III Clinical Trials; Postoperative Period; Research; Research Personnel; Resources; Risk; Source; Treatment Protocols; United States National Institutes of Health; design

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To evaluate, using a random assignment phase II design, two treatment regimens that utilize the EGFR inhibitor C225 in combination with chemoradiation in high-risk postoperative head and neck patients. This trial is designated to determine if either regimen is promising enough to be pursued in a subsequent phase III study.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 采用随机分配II期设计，评价两种使用EGFR抑制剂C225联合放化疗治疗高危头颈部术后患者的治疗方案。 本试验旨在确定两种方案中的任何一种方案是否有足够的希望在随后的III期研究中进行。